Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752973 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
A Phase 2 study of Pediculosis, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT00752973 is a Phase 2 study of Pediculosis that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 12 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT00752973, a Phase 2 study of Pediculosis, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.
Conditions Studied
Interventions
- DRUG MALG (malathion) Treatment
Study Locations (2)
Arkansas
- Investigator Site - Bentonville
- Investigator Site - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00752973
The ClinicalTrials.gov registry entry for NCT00752973 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pediculosis appearing as the primary indexed condition, and to 1 intervention - of which MALG (malathion) Treatment is the first listed.
NCT00752973 reports 2 study locations spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT00752973 about?
NCT00752973 is a clinical study titled "Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice". In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and...
What is the current status of trial NCT00752973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2008-09. Estimated completion is 2012-01.
What conditions does trial NCT00752973 study?
This clinical trial studies the following conditions: Pediculosis.
What interventions are being tested in trial NCT00752973?
The interventions under investigation include: MALG (malathion) Treatment (DRUG).
Who is sponsoring clinical trial NCT00752973?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00752973 being conducted?
This trial has 2 study locations across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.